Goldman Sachs’s Agios Pharmaceuticals AGIO Stock Holding History

Goldman Sachs’s Portfolio AGIO Stock Details AGIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-42,500	Closed	-$1.2M	–	5955
2022 Q3	$1.2M	Buy	+42,500	New	+$1.14M	﹤0.01%	4382
2021 Q4	–	Sell	-27,000	Closed	-$1.25M	–	6440
2021 Q3	$1.25M	Sell	27,000 -25,300	-48%	-$1.22M	﹤0.01%	4581
2021 Q2	$2.88M	Buy	52,300 +20,800	+66%	+$1.16M	﹤0.01%	3863
2021 Q1	$1.63M	Sell	31,500 -24,700	-44%	-$1.22M	﹤0.01%	4181
2020 Q4	$2.44M	Buy	+56,200	New	+$2.22M	﹤0.01%	3578
2020 Q1	–	Sell	-6,600	Closed	-$315K	–	5187
2019 Q4	$315K	Buy	+6,600	New	+$249K	﹤0.01%	4720
2018 Q3	–	Sell	-30,000	Closed	-$2.53M	–	5547
2018 Q2	$2.53M	Buy	+30,000	New	+$2.62M	﹤0.01%	3476
2018 Q1	–	Sell	-41,000	Closed	-$2.34M	–	5871
2017 Q4	$2.34M	Hold	41,000	–	–	﹤0.01%	3648
2017 Q3	$2.74M	Buy	+41,000	New	+$2.46M	﹤0.01%	3704
2015 Q3	–	Sell	-48,700	Closed	-$5.41M	–	7253
2015 Q2	$5.41M	Buy	+48,700	New	+$5.25M	﹤0.01%	2889
2015 Q1	–	Sell	-26,500	Closed	-$2.97M	–	7046
2014 Q4	$2.97M	Buy	+26,500	New	+$2.37M	﹤0.01%	3460

Other funds holding AGIO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Goldman Sachs's AGIO Position: Q2 2026 in Review

Goldman Sachs increased its Agios Pharmaceuticals (AGIO) stake by 43% in Q2 2026, buying an estimated $10.5M and bringing the position to 1,150,932 shares worth $42.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1949.

Goldman Sachs first reported a position in AGIO in Q4 2013 and has held it in 50 quarters since. The position peaked at $110M in Q1 2019. 238 funds tracked by Wall St. Rank hold AGIO as of Q2 2026.

Goldman Sachs held 1,150,932 shares of Agios Pharmaceuticals worth $42.7M as of Q2 2026.
Goldman Sachs bought 345,156 Agios Pharmaceuticals shares in Q2 2026, an estimated $10.5M.
Agios Pharmaceuticals made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #1949 holding.
Goldman Sachs first reported a position in Agios Pharmaceuticals in Q4 2013 and has held it in 50 quarters since.
Goldman Sachs's Agios Pharmaceuticals position peaked at $110M in Q1 2019.
238 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.